Chapter
Current concepts of oncogenes in prostate cancer
pp.：
33 – 41
Tumour suppressor genes in prostate cancer
pp.：
41 – 53
The use of differential display PCR for the detection of new tumor suppressor genes in prostate cancer
pp.：
53 – 63
Molecular alterations associated with prostate cancer development
pp.：
63 – 75
Dysfunction of the cell-cell adhesion complex in lethal prostate cancer
pp.：
75 – 81
Heparan sulfate proteoglycans and prostate cancer: a conceptual framework
pp.：
81 – 91
Androgen receptor mutations in prostate cancer
pp.：
91 – 99
Antiandrogen binding to androgen receptors and the consequences
pp.：
99 – 111
Expression of the MDR1 gene in prostate carcinoma
pp.：
111 – 117
Human prostate cancer progression models and therapeutic intervention
pp.：
117 – 125
Tumor angiogenesis: the VEGF signalling system is a novel target for prostate cancer therapy
pp.：
125 – 135
Antimetastatic approaches to therapy of prostate cancer
pp.：
135 – 143
Intermittent androgen supression: rationale and clinical experience
pp.：
143 – 155
Resistance to drug therapy in cancer: gene therapy approaches to overcome anticancer drug resistance
pp.：
155 – 165
PSA RT-PCR: current status and future potential
pp.：
165 – 171
Special aspects of PSMA and PSA RT-PCR for the detection of disseminated prostate cells
pp.：
171 – 179
Molecular forms of PSA, PSA density, age-/race-specific reference ranges, and PSA velocity
pp.：
179 – 191
Reverse transcriptase-polymerase chain reaction assays used for molecular staging of prostate cancer patients
pp.：
191 – 211
Concluding remarks
pp.：
211 – 221
Molecular Biology of Prostate Cancer
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
